Strengths: “Easy to deal with; explains facts to clients well, and in detail”. Biotechnology and life sciences. Mechanical patents.
Clients: Akebia and Otsuka (respondents) against Astellas and FibroGen over anaemia treatment; Illumina (claimant) against Latvia/MGI over DNA sequencing.
Strengths: “Very thorough and a great strategist”, “top of the game”. Digital communication, life sciences.
Clients: OnePlus, Oppo, OPlus, Xiaomi (defendants) against Mitsubishi and Sisvel over SEPs and FRAND licensing; Teva (claimant) against Bayer over drug sorafenib.
Strengths: “Very smart and easy to work with; makes excellent judgment calls on which points to run”. Pharma and biotechnology, digital communication.
Clients: Merck Sharp Dohme (respondent) against Wyeth over pneumococcal vaccines; Latvia/MGI (defendant) against Illumina over DNA sequencing; Lenovo (defendant) against Interdigital over 3G and 4G technology.
Strengths: “Practical, responsive, robust and clever”. Pharma and biotechnology, SPC cases, digital communication.
Clients: Apple (defendant) against Optis over FRAND; Sky (defendant) against Promptu over subscription television service.
Strengths: Pharma and biotechnology, digital communication.
Clients: Wyeth (appellant) against Merck Sharp Dohme over pneumococcal vaccines; Coloplast (claimant) against Salts Healthcare over ostomy bags; OnePlus, Oppo, OPlus, Xiaomi (defendants) against Mitsubishi and Sisvel over SEPs and FRAND licensing; Philip Morris (defendant) against British American Tobacco/Nicoventures over heat-not-burn cigarette technology; Advanced Bionics (claimant) against MED-EL over cochlear implants.
Strengths: “Smart and easy-going; an excellent IP all-rounder”. Pharma and biotechnology.
Clients: Warner Lambert and Pfizer (defendants) against Dr Reddy's, Teva, NHS England, Wales and Northern Ireland, NHS Scotland, Ranbaxy, et al., over compensation for cross-undertaking in damages in pregabalin trial.
Strengths: “Very bright and extremely clear in his advocacy; a very good client manner”. Pharma and biotechnology, digital communication.
Clients: Vodafone (respondent) against IPCom over access rights; Fibrogen (appellant) and Astellas against Akebia and Otsuka over anaemia treatment; Latvia/MGI (defendant) against Illumina over DNA sequencing.
Strengths: “Thorough and excellent for electronics patents”, “hard-working and formidable”. Digital communication, electronics.
Clients: IPCom (respondent) against Vodafone over access rights; Apple (respondent) against Optis over FRAND and jurisdiction; Voxer (defendant) against Facebook over in-app technology.
Strengths: “One of the wisest counsel at the IP Bar in terms of judgment; his understated demeanour is highly-effective”. Digital communication, mechanics.
Clients: Ocado (appellant) against AutoStore over robotic warehouse systems; Akebia and Otsuka (defendants) against FibroGen and Astellas over anaemia treatment; Illumina (claimant) against Latvia and MGI over DNA sequencing; Dexcom (defendant) against Abbott over medical devices.
Strengths: “Formidable QC – the best for tech patents”. Pharma and biotechnology, medical devices, digital communication. Clients: Mitsubishi and Sisvel (claimants) against OnePlus, Oppo, OPlus, Xiaomi over SEPs and FRAND licensing; BAT/Nicoventures (claimants) against Philip Morris over heat-not-burn cigarette technology.
Strengths: “Excellent for life sciences and tech”, “one of the best around for technically-complex patent disputes”. Pharma and biotechnology.
Clients: Wyeth (appellant) against Merck Sharp Dohme over pneumococcal vaccines; Mitsubishi and Sisvel (claimants) against OnePlus, Oppo, OPlus, Xiaomi over SEPs and FRAND licensing; Roche (defendant) against Insulet over diabetic insulin monitoring device.
The selection of individuals in the above table reflects the research of the editorial staff at JUVE and is based on interviews with clients, lawyers and academics. It remains a subjective view and implies no disparagement of any person not mentioned here but who is nevertheless active in this field. The individuals are listed alphabetically. To find out more about our rankings and research criteria please click here and here.